A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients

Honing, Judith; Smit, Jw; Muijs, Christina T.; Burgerhof, Johannes G. M.; Groot, Jan Willem de; Paardekooper, G.; Müller, Karin; Woutersen, D.; Legdeur, Marie-Cecile; Fiets, W. Edward; Slot, Annerie; Beukema, Jannet C.; Plukker, John; Hospers, Geke A.P.

doi:10.1093/annonc/mdt589

Cited by 110 publications

(119 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We report a median survival duration of 15 months in the group receiving carboplatin-paclitaxel, which is similar to the duration seen in previous reports 8,19 . The median os duration for dcrt with cisplatin-5fu reported in phase iii trials ranged from 14 to 18 months 7,20,21 .…”

Section: Discussionsupporting

confidence: 90%

“…A retrospective review by Blom et al 14 reported that, in trimodality management, outcomes were comparable but treatment-related toxicity was less for carboplatin-paclitaxel and a rt dose of 41.4 Gy compared with cisplatin-5fu and a rt dose of 50.4 Gy. Honing et al 8 did not find a significant difference in survival between the two chemotherapy regimens in the definitive setting, reporting a median survival duration of 16.1 months (95% ci: 11.8 to 20.5 months) in the cisplatin-5fu group and 13.8 months (95% ci: 10.8 to 16.9 months) in carboplatin-paclitaxel group (p = 0.879). The current U.S. National Comprehensive Cancer Network guideline recommends carboplatin-paclitaxel as one of the preferred regimens in dcrt 4 .…”

Section: Discussionmentioning

confidence: 95%

“…This chemotherapy regimen has also started to be preferred for patients receiving dcrt because of better tolerance and less toxicity 6,8,14 . In the present study, we report a slightly higher incidence of grade 3 toxicities than was reported in the cross trial (hematologic: 12% vs. 8%; nonhematologic: 35% vs. 13%) and a higher incidence of esophagitis (23% vs. 1%).…”

Section: Discussionmentioning

confidence: 99%

“…To our knowledge, only one retrospective study has compared carboplatin-paclitaxel with cisplatin-5fu, reporting comparable outcomes for the two groups in that setting 8 . The objective of the present study was to evaluate tolerability, toxicity, and outcomes in patients with localized esophageal and gej cancer who received dcrt using any of cisplatin-5fu, carboplatin-5fu, or carboplatin-paclitaxel at our institute.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Shifting Practice in Definitive Chemoradiation for Localized Esophageal Cancer

Biagi

Hopman

et al. 2017

Current Oncology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Shifting Practice in Definitive Chemoradiation for Localized Esophageal Cancer

Biagi

Hopman

et al. 2017

Current Oncology

View full text Add to dashboard Cite

show abstract

“…Radiotherapy was applied with single doses of 1.8 to 2.0 Gy up to a total dose of 50. vs. 131 patients with localised SCC the authors reported a significantly improved progression free and OS (P=0.009) in favour of the latter regimen, but it remains unclear whether results were driven by including a taxane into the experimental group or by the reduced dose of cisplatin and the unusual dose of 5-FU in the so called standard group of this analysis. A group from the Netherlands reported on their experience with adapting the CROSS-regimen for dCRT (32). This retrospective study analysed patients with locally advanced oesophageal or junctional cancer who had received dCRT to a total dose of 46.8-70 Gy (and additional intraluminal brachytherapy in single patients) either combined with four cycles of cisplatin and 5-FU (RTOG 8501-regimen) (n=47) or with 5-6 weekly applications of carboplatin (AUC 2) and Paclitaxel (50 mg/m 2 ) (n=55).…”

Section: Which Chemotherapy To Use For Combined Definitive Crt?mentioning

confidence: 99%

Definitive chemoradiotherapy

Ståhl¹,

Budach²

2017

J. Thorac. Dis.

View full text Add to dashboard Cite

Definitive chemoradiotherapy (dCRT) is reflecting a treatment standard in oesophageal cancer.For irresectable localised tumours and for inoperable patients, dCRT can change the treatment intent from palliative to curative. In patients with squamous cell carcinoma (SCC), in particular in those of cervical location, dCRT is a proper alternative for treatment that may include radical surgery. Patients with localised locoregional recurrence after primary surgery can survive for long-term after salvage CRT.

show abstract

Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer

Wei³

et al. 2022

JAMA Netw Open

View full text Add to dashboard Cite

IMPORTANCE Multiple paclitaxel-based regimens are widely used in chemoradiation therapy against esophageal cancer, including regimens combining paclitaxel with fluorouracil, cisplatin, and carboplatin. However, which among these 3 regimens provides the best prognosis with minimum adverse events is still unknown. OBJECTIVE To compare the efficacy and adverse events of fluorouracil, cisplatin, and carboplatin in definitive chemoradiotherapy in patients with esophageal squamous cell carcinoma (ESCC). DESIGN, SETTING, AND PARTICIPANTSThis randomized clinical trial of patients with ESCC was conducted in 11 treatment centers in China. Eligible patients were aged 18 to 75 years and had histologically confirmed ESCC stages IIa to IVa with no prior treatment, Eastern Cooperative Oncology Group performance status of 2 or lower, and adequate organ functions. The study was conducted between July 2015 and February 2018, and the cutoff date for data analysis was August 31, 2020. INTERVENTIONS Patients with locally advanced ESCC were randomly assigned (1:1:1) to groups combining paclitaxel treatment with fluorouracil, cisplatin, or carboplatin. Patients in the cisplatin group were treated with 2 cycles of concurrent chemoradiotherapy followed by 2 cycles of consolidation chemotherapy with monthly paclitaxel plus cisplatin. For the fluorouracil group, patients were administered 6 cycles of weekly paclitaxel plus fluorouracil in concurrent chemoradiotherapy followed by 2 cycles of monthly paclitaxel plus fluorouracil in consolidation chemotherapy. Patients in the carboplatin group were treated with 6 cycles of weekly paclitaxel plus carboplatin in concurrent chemoradiotherapy followed by 2 cycles of monthly paclitaxel plus carboplatin in consolidation chemotherapy. All patients received radiotherapy of 61.2 Gy delivered in 34 fractions. MAIN OUTCOMES AND MEASURES The primary end point was overall survival (OS). The secondary end points were progression-free survival and adverse events. RESULTS Overall, 321 patients (median [IQR] age, 64 years [59-69 years]; 248 [77.3%] men) with ESCC from 11 centers were randomized into fluorouracil, cisplatin, or carboplatin groups between July 2015 and February 2018. Over a median (IQR) follow-up time of surviving patients of 46.0 months (36.6-53.0 months), the 3-year OS rates were 57.2% in the fluorouracil group, 60.1% in the cisplatin group, and 56.5% in the carboplatin group, respectively (fluorouracil vs cisplatin: HR, 1.06; 95% CI, 0.71-1.60; P = .77; fluorouracil vs carboplatin: HR, 0.94; 95% CI, 0.63-1.40; P = .77). The cisplatin group had significantly higher incidences of acute grade 3 or 4 neutropenia (69 events (continued) Key Points Question Which paclitaxel-based regimen, among fluorouracil, cisplatin, and carboplatin, provides the best prognosis with minimum adverse events for patients with locally advanced esophageal squamous cell carcinoma? Findings In this randomized clinical trial of 321 patients with esophageal squamous cell carcinoma treated in 11 cancer centers in China, th...

show abstract

A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients

Cited by 110 publications

References 14 publications

Shifting Practice in Definitive Chemoradiation for Localized Esophageal Cancer

Shifting Practice in Definitive Chemoradiation for Localized Esophageal Cancer

Definitive chemoradiotherapy

Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer

Contact Info

Product

Resources

About